Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Ostrowitzki, Susanne; Lasser, Robert; Dorflinger, Ernest; Scheltens, Philip; Barkhof, Frederik; Nikolcheva, Tania; Ashford, Elizabeth; Retout, Sylvie; Hofmann, Carsten; Delmar, Paul; Klein, Gregory; Andjelković, Mirjana; Dubois, Bruno; Boada, Merçé; Blennow, Kaj; Fontoura, Paulo

doi:10.1186/s13195-018-0409-4

Cited by 7 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Later, the data from passive immunotherapy trials showed that ARIA-edema/effusion incidence was dose-and APOE (apolipoprotein E) ε4-dependent. [14][15][16] Indeed, the APOE ε4 allele has been identified as a risk factor for both AD and CAA 7 and is associated with more severe CAA, even controlling for the extent of AD pathology. 17 Therefore, APOE ε4 carriers have a relatively high CAA burden for the severity of concomitant AD.…”

Section: Caa and Ariamentioning

confidence: 99%

Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab

Sveikata

Charidimou

Viswanathan

2022

Stroke

View full text Add to dashboard Cite

We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.

show abstract